Bank of New York Mellon Corp Makes New $2.91 Million Investment in Maze Therapeutics, Inc. $MAZE

Key Points

• Bank of New York Mellon acquired 97,588 Maze Therapeutics shares worth approximately $2.91 million, representing about 0.18% of the company; several other institutions also increased or initiated positions.
• Maze insiders have been selling shares, including CEO Jason Coloma’s $907,000 sale and CMO Harold Bernstein’s $446,000 sale. Insiders sold 209,612 shares worth roughly $5.7 million over the past 90 days, with the transactions conducted under pre-arranged plans or for tax obligations.
• Analyst sentiment remains broadly positive, with a consensus “Buy” rating and a $66 price target, but MAZE trades below its moving averages and remains loss-making, reporting quarterly EPS of negative $0.76 and projected annual EPS of negative $2.72.

Bank of New York Mellon Corp bought a new stake in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 97,588 shares of the company's stock, valued at approximately $2,912,000. Bank of New York Mellon Corp owned about 0.18% of Maze Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of MAZE. Royal Bank of Canada lifted its holdings in Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company's stock valued at $27,000 after buying an additional 363 shares during the period. Ameritas Investment Partners Inc. grew its holdings in Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock worth $42,000 after acquiring an additional 738 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in Maze Therapeutics during the 4th quarter worth $43,000. Russell Investments Group Ltd. raised its position in shares of Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company's stock valued at $49,000 after acquiring an additional 1,725 shares during the last quarter. Finally, Legal & General Group Plc raised its position in shares of Maze Therapeutics by 387.0% during the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company's stock valued at $52,000 after acquiring an additional 3,371 shares during the last quarter.

Insider Buying and Selling at Maze Therapeutics

In other Maze Therapeutics news, CEO Jason Coloma sold 34,501 shares of the stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $26.29, for a total value of $907,031.29. Following the completion of the sale, the chief executive officer directly owned 18,151 shares in the company, valued at $477,189.79. This represents a 65.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of the firm's stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $27.61, for a total value of $445,680.62. Following the sale, the chief marketing officer directly owned 16,142 shares in the company, valued at approximately $445,680.62. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 209,612 shares of company stock valued at $5,734,575. Company insiders own 5.30% of the company's stock.

Maze Therapeutics Stock Performance

MAZE opened at $26.21 on Monday. The firm's fifty day moving average is $28.69 and its two-hundred day moving average is $31.06. The firm has a market cap of $1.46 billion, a PE ratio of -10.40 and a beta of 2.17. Maze Therapeutics, Inc. has a twelve month low of $14.27 and a twelve month high of $53.65. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting analysts' consensus estimates of ($0.76). Equities research analysts anticipate that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

Trending Headlines about Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Analysts Set New Price Targets

MAZE has been the topic of several recent research reports. BTIG Research restated a "buy" rating and issued a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. TD Cowen upgraded Maze Therapeutics to a "strong-buy" rating in a report on Monday, August 24th. Finally, Wall Street Zen cut Maze Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Maze Therapeutics has a consensus rating of "Buy" and a consensus price target of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

Want to see what other hedge funds are holding MAZE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.